ClinicalTrials.gg
CompletedNCT00644553Updated Mar 27, 2008

Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis

A Phase 3 interventional study of Clarithromycin and Amoxicillin in Acute Bacterial Sinusitis (ABS), sponsored by Abbott. Completed at 53 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2008-03-27.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
437
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing amoxicillin in Sinusitis — 2 open to participants now, 2 under way, none of them phase 3. Amoxicillin · Sinusitis.

Enrollment
5th of 10
437 · median 376
Started
2003
the only one that year
Phase 3
2 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
1 of 10
Abbott

Among the 10 studies testing amoxicillin in Sinusitis, this one is the 5th largest by enrollment, is the only one that started in 2003, is one of 2 in phase 3, and was the 5th registered.

Sinusitis

256 studies on the registry are indexed under Sinusitis; 23 are open to participants now.

Browse Sinusitis studies →

Open to participants now

2 of the 10 studies testing amoxicillin in Sinusitis are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About amoxicillin

Amoxicillin: first FDA approval 1974 (AMOXIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 15 Sinusitis studies recruiting now, 6 (40%) set no upper age limit and 6 (40%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing amoxicillin in Sinusitis, or all of them as a file.
02

Study summary

To compare the safety/tolerability and efficacy of a 14-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 14-day course of amoxicillin-clavulanate tablets (875/125 mg BID) for the treatment of ambulatory subjects with Acute Bacterial Sinusitis (ABS).

03

Conditions studied

  • Acute Bacterial Sinusitis (ABS)

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The female must be non-lactating and at no risk for pregnancy.
  • Subject must have a diagnosis of ABS. The diagnosis must be based on the following:

    • A sinus radiograph (Water's view) or CT scan with evidence of maxillary opacification or
    • Air/fluid levels purulent discharge from the nose
    • At least two of the following additional signs and symptoms lasting longer than seven days prior to and no longer than 28 days before Evaluation 1.
    • A pre-treatment sample from a sinus puncture or
    • Middle meatus endoscopy must be obtained for bacterial aerobic culture
    • Susceptibility testing (applicable only for selected investigative sites).
  • Subject must be a suitable candidate for oral antibiotic therapy and able to swallow tablets intact.

Exclusion criteria

Exclusion Criteria:

  • A medical history of or allergic reactions to clarithromycin, erythromycin, amoxicillin/clavulanate, any penicillin or any of the macrolide antibiotics.
  • History of amoxicillin-clavulanate associated cholestatic jaundicehepatic dysfunction.
  • Females who are pregnant or lactating.
  • Subject has either of the following:

    • Chronic sinusitis (signs and symptoms lasting longer than 28 days immediately prior to Evaluation 1)
    • Significant anatomical abnormalities of the sinuses any other infection or
    • Condition which necessitates use of a concomitant systemic antibiotic.
  • Evidence of uncontrolled cardiovascular, pulmonary, metabolic, gastrointestinal, neurological, psychiatric or endocrine disease, , or other abnormality (other than the disease being studied).
  • Any underlying condition/disease, that would be likely to interfere with the completion of the course of study drug therapy or follow-up.
  • Known significant renal or hepatic impairment (or disease).
  • Subject who has taken: a systemic antibiotic within 2 weeks before study drug administration or a long-acting injectable antibiotic (e.g., penicillin G benzathine) within 4 weeks before study drug administration.
  • subjects (e.g., neutropenic subjects).
  • Subjects with known infection.
  • Treatment with any other drug within 4 weeks prior to study drug administration.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
437 participants (actual)

Study arms

  • Active comparator
    A

    Drug: Clarithromycin

  • Active comparator
    B

    Drug: Amoxicillin

Interventions

  • Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)

    Also known as: ABT-268, Biaxin

  • Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)

    Also known as: amoxicillin-clavulanate

06

What researchers measure

Primary outcomes

  1. Clinical Response

    Time frame: 33 days

Secondary outcomes

  1. Radiographic Response

    Time frame: 33 days

07

Study locations

53 sites
  • Birmingham, Alabama 35235, United States
  • Phoenix, Arizona 85014, United States
  • Clovis, California 93611, United States
  • La Jolla, California 92037, United States
  • San Luis Obispo, California 93405, United States
  • Coeur d'Alene, Idaho 83814, United States
  • Charlotte, North Carolina 28210, United States
  • Columbus, Ohio 43235, United States
  • Eugene, Oregon 97404, United States
  • Johnson City, Tennessee 37601, United States
  • San Antonio, Texas 78209, United States
  • Spokane, Washington 99216, United States
  • Kitchener, Ontario N2C 2N9, Canada
  • Toronto, Ontario M9W 4L6, Canada
  • Sherbrooke, Quebec J1J 2B8, Canada
  • Saskatoon, Saskatchewan S7H 0W6, Canada
  • Athens, 115 27, Greece
  • Athens, 11522, Greece
  • Patra, 26500, Greece
  • Piraeus, 18454, Greece
  • Thessaloniki, 54636, Greece
  • Thessaloniki, 56430, Greece
  • Budapest, H-1062, Hungary
  • Budapest, H-1096, Hungary
  • Budapest, H-1097, Hungary
  • Budapest, H-1106, Hungary
  • Salgotarjan, H-3100, Hungary
  • Szombathely, H-9700, Hungary
  • Veszprem, H-8200, Hungary
  • Catania, 95124, Italy
  • Genova, 16132, Italy
  • Padova, 35128, Italy
  • Palermo, 90127, Italy
  • Pavia, 27100, Italy
  • Kaunas, LT-3007, Lithuania
  • Vilnius, LT-2014, Lithuania
  • Vilnius, LT-2021, Lithuania
  • Vilnius, LT-2025, Lithuania
  • Bialystok, 15-276, Poland
  • Bielsko-Biala, 43-300, Poland
  • Bydgoszcz, 85-090, Poland
  • Gliwice, 44-100, Poland
  • Jelenia Gora, 58-506, Poland
  • Lublin, 20-954, Poland
  • Wroclaw, 50-368, Poland
  • Wroclaw, 51-124, Poland
  • Bucharest, 762631, Romania
  • Bucharest, 773511, Romania
  • Badajoz, 06010, Spain
  • Barcelona, 08036, Spain
  • Madrid, 28805, Spain
  • Palma de Mallorca, 07014, Spain
  • Valladolid, 47002, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2003 and a primary completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2008
First posted
Mar 27, 2008
Start
May 2003
Primary completionActual
Mar 2004
Last update
Mar 27, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00644553
Lead sponsor
Abbott
First posted
Mar 27, 2008
Start date
May 2003
Primary completion
Mar 2004
Last update
Mar 27, 2008
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clarithromycin · Amoxicillin

Start the discussion